<DOC>
	<DOC>NCT01432223</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy in terms of the pathological complete response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based regimen followed by Nab-paclitaxel and Trastuzumab in patients with HER2 positive operable breast cancer.</brief_summary>
	<brief_title>Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab</brief_title>
	<detailed_description>Four cycles of anthracycline-based regimen followed by four cycles of Nab-paclitaxel and Trastuzumab are administrated. Anthracycline-based regimen (d1, q3w): EC (Epirubicin 90mg/m2 and Cyclophosphamide 600mg/m2) AC (Doxorubicin 60mg/m2 and Cyclophosphamide 600mg/m2) FEC (Fluorouracil 500mg/m2, Epirubicin 100mg/m2 and Cyclophosphamide 500mg/m2) Nab-paclitaxel 260mg/m2 (d1, q3w) Trastuzumab (d1, q3w) is given at a dose of 8 mg/kg IV on day 1 of the first treatment cycle over 90 min, and subsequently given at a dose of 6 mg/kg over 30 min.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirmed invasive breast cancer T1c3 N02a Confirmed of hormonal receptor status HER2 positive confirmed by IHC 3+ or FISH+ LVEF &gt; 50% by echocardiogram or MUGA Adequate EKG No prior treatment for breast cancer PS 01 Required baseline laboratory data WBC &gt; 4,000/mm3 and Neut &gt; 2,000/mm3 PLT &gt; 100,000/mm3 Hb &gt; 9.0g/dl AST and ALT &lt; ULNx2.5 TBil &lt; 1.5mg/dl Serum creatinin &lt; 1.5mg/dl Written informed consent With history of hypersensitivity reaction for important drug in this study With history of invasive breast cancer Bilateral invasive breast cancer Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus Positive for HBs antigen and with history of HVB With history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction, poorly controlled hypertension With severe edema With severe peripheral neuropathy With severe psychiatric disorder Pregnant or nursing women Cases who physician judged improper to entry this trial</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Trastuzumab</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Primary chemotherapy</keyword>
</DOC>